EXEL vs. GMAB: Exelixis vs. Genmab Stock Comparison
How do Exelixis (EXEL) and Genmab (GMAB) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Exelixis (EXEL) and Genmab (GMAB) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
Exelixis (EXEL) trades as ordinary local shares, while Genmab (GMAB) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | EXEL | GMAB |
|---|---|---|
| Name | Exelixis Inc. | Genmab A/S American Depositary Shares |
| Country/Region | United States | Denmark |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 16.98 billion USD | 32.98 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | April 17, 2000 | June 1, 2009 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | EXEL | GMAB |
|---|---|---|
| Total Return (1Y) | 74.98% | 91.17% |
| Total Return (3Y, Annualized) | 50.33% | 20.70% |
| Total Return (5Y, Annualized) | 31.10% | 3.98% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | EXEL | GMAB |
|---|---|---|
| Volatility (1Y, Annualized) | 34.17% | 45.68% |
| Beta (5Y) | 0.41 | 0.72 |
| Max Drawdown (5Y) | -35.41% | -61.79% |
| Avg. Volume (3M) | 2.33M | 4.09M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | EXEL | GMAB |
|---|---|---|
| Sharpe Ratio (1Y) | 2.07 | 1.90 |
| Sortino Ratio (1Y) | 3.23 | 3.82 |
Profitability
ROE (TTM)
Both Exelixis (EXEL) at 44.32% and Genmab (GMAB) at 12.07% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
44.32%
- Max
- 109.18%
- EXEL
- 44.32%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
12.07%
- Max
- 109.18%
- GMAB
- 12.07%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Exelixis (EXEL) at 35.45% keeps the most of each sales dollar — above its industry’s net margin range — and Genmab (GMAB) at 16.97% also retains a top-quartile share.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
35.45%
- EXEL
- 35.45%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.97%
- Max
- 18.05%
- GMAB
- 16.97%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Exelixis (EXEL) at 40.75% and Genmab (GMAB) at 37.15% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
40.75%
- Max
- 83.12%
- EXEL
- 40.75%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
37.15%
- Max
- 83.12%
- GMAB
- 37.15%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | EXEL | GMAB |
|---|---|---|
| ROE (TTM) | 44.32% | 12.07% |
| ROA (TTM) | 23.52% | 8.24% |
| Net Margin (TTM) | 35.45% | 16.97% |
| Operating Margin (TTM) | 40.75% | 37.15% |
| Gross Margin (TTM) | 96.26% | 92.67% |
Growth
Revenue Growth
Both Exelixis (EXEL) at 6.98% and Genmab (GMAB) at 19.19% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Both Exelixis (EXEL) at 57.95% and Genmab (GMAB) at -9.23% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | EXEL | GMAB |
|---|---|---|
| Revenue Growth (YoY) | 6.98% | 19.19% |
| Revenue Growth (3Y CAGR) | 12.93% | 21.23% |
| EPS Growth (YoY) | 57.95% | -9.23% |
| EPS Growth (3Y CAGR) | 70.59% | 8.48% |
Financial Strength
Current Ratio (MRQ)
Exelixis (EXEL) at 3.21 keeps current ratio within its industry’s typical mid-range, while Genmab (GMAB) at 2.45 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GMAB.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.21
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- EXEL
- 3.21
- Q1
- 2.47
- Min
- 0.10
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.45
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- GMAB
- 2.45
- Min
- 0.10
Debt / Equity (MRQ)
Exelixis (EXEL) at 0.09 carries an industry-typical debt-to-equity mix, while Genmab (GMAB) at 0.82 uses more debt funding than most peers.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.09
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- EXEL
- 0.09
- Q1
- 0.02
- Min
- 0.00
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.82
- Max
- 1.42
- GMAB
- 0.82
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | EXEL | GMAB |
|---|---|---|
| Current Ratio (MRQ) | 3.21 | 2.45 |
| Debt / Equity (MRQ) | 0.09 | 0.82 |
| Net Debt / EBITDA | -0.71 | 2.45 |
Dividends
Dividend Yield (TTM)
Neither Exelixis (EXEL) nor Genmab (GMAB) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- EXEL
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- GMAB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Exelixis (EXEL) nor Genmab (GMAB) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- EXEL
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- GMAB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | EXEL | GMAB |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Exelixis (EXEL) at 20.83 is near its industry’s usual P/E ratio, while Genmab (GMAB) at 45.84 sits in the richer quartile — GMAB needs stronger growth or earnings quality to justify the premium.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.83
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- EXEL
- 20.83
- Q1
- 13.30
- Min
- 0.07
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
45.84
- Max
- 85.34
- GMAB
- 45.84
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Exelixis (EXEL) at 6.80 and Genmab (GMAB) at 7.68 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.80
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- EXEL
- 6.80
- Q1
- 3.01
- Min
- 0.01
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.68
- Max
- 58.18
- Q3
- 25.77
- GMAB
- 7.68
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Genmab (GMAB) at 5.36 is valued about in line with its industry on P/B ratio, while Exelixis (EXEL) at 9.28 carries an above-peer premium to book — EXEL is pricier on assets.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.28
- Max
- 13.53
- EXEL
- 9.28
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.36
- Max
- 13.53
- Q3
- 6.54
- GMAB
- 5.36
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | EXEL | GMAB |
|---|---|---|
| P/E Ratio (TTM) | 20.83 | 45.84 |
| P/S Ratio (TTM) | 6.80 | 7.68 |
| P/B Ratio (MRQ) | 9.28 | 5.36 |
| Free Cash Flow Yield (TTM) | 4.47% | 2.59% |